🔥🐔 BizChicken 🐔🔥

Companies Similar to Capricor Therapeutics, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Applied Therapeutics, Inc.

Applied Therapeutics, Inc. logo
Market Cap: Medium
Employees: Lowest

AT-007

Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products targeting cardiovascular disease, galactosemia, and diabetic complications. Key products include AT-007 and AT-001.

Tags: biopharmaceutical, cardiovascular disease, clinical trials, diabetic complications, galactosemia

Symbol: APLT

Recent Price: $0.81

Industry: Biotechnology

CEO: Dr. Shoshana Shendelman Ph.D.

Sector: Healthcare

Employees: 31

Address: 545 Fifth Avenue, New York, NY 10017

Phone: 212 220 9226

Leadership

  • Shoshana Shendelman, Chair, Board of Directors
  • Riccardo Perfetti, Chief Medical Officer
  • Les Funtleyder,
  • Dale Hooks, Chief Commercial Officer
  • Constantine Chinoporos, Chief Business Officer / Chief Operating Officer
  • Joel Marcus,
  • Jay Skyler,
  • Stacy Kanter,
  • Teena Lerner,
  • Donald Landry M.D., Ph.D., Chair, Scientific Advisory Board
  • Roy Freeman M.D.,
  • Roxana Mehran M.D.,
  • Lawrence Steinman M.D.,
  • Gregg Stone M.D.,
  • Donald d'Amico M.D.,
  • Donald Landry, Chair, Scientific Advisory Board
  • Roy Freeman,
  • Roxana Mehran,
  • Lawrence Steinman,
  • Gregg Stone,
  • Donald d'Amico,

Last updated: 2024-12-31

Capricor Therapeutics, Inc.

Capricor Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

CAP-1002

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company specializing in developing transformative cell and exosome-based therapeutics aimed at treating and preventing a range of diseases and disorders. Their lead candidate, CAP-1002, is designed for Duchenne muscular dystrophy and cytokine storm interventions.

Tags: COVID-19, Duchenne muscular dystrophy, biotechnology, cell therapy, therapeutics

Symbol: CAPR

Recent Price: $13.76

Industry: Biotechnology

CEO: Dr. Linda Marbán Ph.D.

Sector: Healthcare

Employees: 101

Address: 10865 Road to the Cure, San Diego, CA 92121

Phone: 310 358 3200

Leadership

  • Linda Marbán, Ph.D., Chief Executive Officer and Director
  • Kristi A. H. Elliott, Ph.D., Chief Science Officer
  • AJ Bergmann, M.B.A., Chief Financial Officer
  • Karen G. Krasney, J.D., Executive Vice President and General Counsel
  • Mark Awadalla, Vice President of Clinical Operations
  • Jonathan Tayco, Vice President of Program Management and Business Operations
  • Minghao Sun, Ph.D., Vice President of Research and Product Development
  • Yushi Feng, Ph.D., Vice President of Regulatory Affairs
  • Frank Litvack M.D., FACC, Executive Chairman
  • Paul G. Auwaerter, M.D., M.B.A., FIDSA, Director
  • Earl M. (Duke) Collier Jr., Director
  • George W. Dunbar, Jr., Director
  • Philip J. Gotwals, Ph.D., Director
  • Michael Kelliher, Director
  • David B. Musket, Director
  • Karimah Es Sabar, Director

Last updated: 2024-12-31

Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

ELI-002

Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for cancer and other diseases, with its lead product ELI-002 targeting KRAS-driven cancers.

Tags: Biotechnology, Cancer Treatment, Clinical-stage, Immunotherapy, Vaccines

Symbol: ELTX

Recent Price: $5.00

Industry: Biotechnology

CEO: Mr. Robert T. Connelly

Sector: Healthcare

Employees: 32

Address: 451 D Street, Boston, MA 02210

Phone: 857-209-0050

Last updated: 2024-12-31

Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc. logo
Market Cap: Low
Employees: Low

Therapeutic Candidates (INBRX-109, INBRX-106)

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops biologic therapeutics for life-threatening conditions, with therapeutic candidates in phase 2 clinical trials targeting various cancers.

Tags: biologic therapeutics, biopharmaceutical, cancer treatment, clinical-stage

Symbol: INBX

Recent Price: $15.14

Industry: Biotechnology

CEO: Mr. Mark Paul Lappe

Sector: Healthcare

Employees: 166

Address: 11025 North Torrey Pines Road, La Jolla, CA 92037

Phone: 858-795-4220

Last updated: 2024-12-31

Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

zilovertamab, ONCT-216, ONCT-808, ONCT-534

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology therapies for cancers with significant unmet medical needs, featuring a pipeline that includes the monoclonal antibody zilovertamab and various other targeted treatments.

Tags: CAR-T, ROR1, antibody, biopharmaceutical, cancer therapy, clinical-stage, oncology

Symbol: ONCT

Recent Price: $0.53

Industry: Biotechnology

CEO: Dr. James B. Breitmeyer M.D., Ph.D.

Sector: Healthcare

Employees: 27

Address: 12230 El Camino Real, San Diego, CA 92130

Phone: 858 434 1113

Last updated: 2024-12-31

Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc. logo
Market Cap: Highest
Employees: Medium

EXONDYS 51, VYONDYS 53, AMONDYS 45, SRP-5051, SRP-9001, SRP-9003

Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA-targeted therapeutics and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy.

Tags: Duchenne muscular dystrophy, RNA-targeted therapeutics, biopharmaceutical, gene therapy, rare diseases

Symbol: SRPT

Recent Price: $121.19

Industry: Biotechnology

CEO: Mr. Douglas S. Ingram Esq.

Sector: Healthcare

Employees: 1314

Address: 215 First Street, Cambridge, MA 02142

Phone: 617 274 4000

Leadership

  • Douglas S. Ingram, President and Chief Executive Officer
  • Bilal Arif, Executive Vice President, Chief Technical Operations Officer
  • Diane Berry, PhD, Executive Vice President, Chief Global Policy & Advocacy Officer
  • Ryan E. Brown, JD, Executive Vice President, Chief General Counsel
  • Ian M. Estepan, Executive Vice President, Chief Financial Officer
  • Dallan Murray, Executive Vice President, Chief Customer Officer
  • Alison Nasisi, Executive Vice President, Chief People Officer
  • Louise R. Rodino-Klapac, PhD, Executive Vice President, Head of R&D, Chief Scientific Officer
  • Will Tilton, Senior Vice President, Head of Strategy, Chief of Staff
  • M. Kathleen Behrens, PhD, Chairwoman
  • Richard J. Barry,
  • Kathryn Boor, PhD,
  • Michael Chambers,
  • Deirdre Connelly,
  • Stephen L. Mayo, PhD,
  • Claude Nicaise, MD,
  • Hans Wigzell, MD, PhD,
  • John C. Martin, PhD (In Memoriam),
  • Annemieke Aartsma-Rus, PhD,
  • Carsten Bönnemann, MD,
  • Joy Cavagnaro, PhD, DABT, Fellow ATS,
  • Kay Davies, PhD, DBE FMedSci FRS,
  • Steven Gray, PhD,
  • Angela J. Russell, DPhil,

Last updated: 2024-12-31

Telomir Pharmaceuticals, Inc. Common Stock

Telomir Pharmaceuticals, Inc. Common Stock logo
Market Cap: Low
Employees: Lowest

TELOMIR-1

Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on developing and commercializing therapies for age-related inflammatory conditions and post-chemotherapy recovery.

Tags: TELOMIR-1, inflammatory conditions, pharmaceutical, stem cells, therapeutic treatment

Symbol: TELO

Recent Price: $4.64

Industry: Biotechnology

CEO: Mr. Erez Aminov

Sector: Healthcare

Employees: 1

Address: 855 N Wolfe Street, Baltimore, null 21205

Phone: (737)-289-0835

Last updated: 2024-12-31

Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. logo
Market Cap: High
Employees: Low

therapeutic monoclonal and bispecific antibodies

Celldex Therapeutics is a biopharmaceutical company focused on developing therapeutic monoclonal and bispecific antibodies for treating inflammatory diseases and cancers.

Tags: biopharmaceutical, bispecific antibodies, cancer treatment, inflammatory diseases, monoclonal antibodies

Symbol: CLDX

Recent Price: $25.12

Industry: Biotechnology

CEO: Mr. Anthony S. Marucci M.B.A.

Sector: Healthcare

Employees: 160

Address: Perryville III Building, Hampton, NJ 08827

Phone: 908 200 7500

Leadership

  • Anthony S. Marucci, Founder, President, Chief Executive Officer and Director
  • Tibor Keler, Ph.D., Founder, Executive Vice President and Chief Scientific Officer
  • Diane C. Young, M.D., Senior Vice President and Chief Medical Officer
  • Elizabeth Crowley, Senior Vice President, Chief Product Development Officer
  • Sam Martin, Senior Vice President and Chief Financial Officer
  • Ronald A. Pepin, Ph.D., Senior Vice President and Chief Business Officer
  • Richard Wright, Ph.D., Senior Vice President and Chief Commercial Officer
  • Sarah Cavanaugh, Senior Vice President, Corporate Affairs and Administration
  • Margo Heath-Chiozzi, M.D., Senior Vice President, Regulatory Affairs
  • Freddy A. Jimenez, Esq., Senior Vice President and General Counsel
  • Karen L. Shoos, J.D., Former Chair, Director of Operations, Maryland Tech Council Venture Mentoring Services Program
  • Keith L. Brownlie, Former Partner, Ernst & Young LLP
  • Herbert J. Conrad, Former President, Roche Pharmaceuticals US
  • James J. Marino, J.D., Former Partner, Dechert LLP
  • Harry H. Penner, Jr., J.D., L.L.M., Former Chairman and CEO, Nascent Bioscience
  • Cheryl L. Cohen, President, CLC Consulting; Former Chief Commercial Officer of Medivation, Inc.
  • Dr. Garry Neil, Chief Executive Officer; Chair of the Board, Avalo Therapeutics
  • Rita Jain, M.D., Former Executive Vice President, Chief Medical Officer of ChemoCentryx, Inc.
  • Carl June, M.D.,
  • Michel Nussenzweig, M.D., Ph.D.,
  • Marc E. Rothenberg M.D., Ph.D.,
  • Joseph Schlessinger, Ph.D.,
  • Louis Weiner, M.D.,

Last updated: 2024-12-31

Compass Therapeutics, Inc.

Compass Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CTX-009, CTX-471, CTX-8371

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics to treat various human diseases. Their clinical stage products include investigational bispecific antibodies like CTX-009 and monoclonal antibodies such as CTX-471.

Tags: CTX-009, CTX-471, CTX-8371, antibody therapeutics, biopharmaceutical, clinical stage, oncology

Symbol: CMPX

Recent Price: $1.48

Industry: Biotechnology

CEO: Dr. Thomas J. Schuetz M.D., Ph.D.

Sector: Healthcare

Employees: 32

Address: 80 Guest Street, Boston, MA 02135

Phone: 617 500 8099

Last updated: 2024-12-31

Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

CC-31244, CC-42344

Cocrystal Pharma, Inc. is a biotechnology company specializing in the discovery and development of antiviral drugs for tackling serious and chronic viral diseases such as hepatitis C, influenza, coronavirus, and norovirus.

Tags: antiviral, biotechnology, coronavirus, hepatitis C, influenza, norovirus

Symbol: COCP

Recent Price: $3.25

Industry: Biotechnology

CEO: Dr. Sam Lee Ph.D.

Sector: Healthcare

Employees: 12

Address: 19805 North Creek Parkway, Bothell, WA 98011

Phone: 786 459 1831

Leadership

  • Sam Lee, Ph.D., Co-Chief Executive Officer and President
  • James J. Martin, Co-Chief Executive Officer and Chief Financial Officer
  • Roger Kornberg, Chairman of the Board, Chief Scientist and Chairman of Scientific Advisory Board
  • Steve Rubin, Vice Chairman
  • Phillip Frost, Director
  • Fred Hassan, Director
  • Anthony Japour, President, CEO and Director
  • Richard C. Pfenniger, Jr., Director

Last updated: 2024-12-31

4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

4D-125, 4D-110, 4D-310, 4D-150, 4D-710

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company developing product candidates using adeno-associated virus vectors, focusing on ophthalmology, cardiology, and pulmonology.

Tags: biotechnology, cardiology, gene therapy, ophthalmology, pulmonology

Symbol: FDMT

Recent Price: $5.30

Industry: Biotechnology

CEO: Dr. David H. Kirn M.D.

Sector: Healthcare

Employees: 201

Address: 5858 Horton Street, EmeryVille, CA 94608

Phone: 510 505 2680

Last updated: 2024-12-31

Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Decoy20

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company focusing on the development of anti-cancer and anti-viral immunotherapy products, with its lead clinical candidate, Decoy20, targeting lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as viral infections.

Tags: Decoy20, anti-cancer, anti-viral, biotechnology, immunotherapy

Symbol: INDP

Recent Price: $0.87

Industry: Biotechnology

CEO: Mr. Jeffrey A. Meckler

Sector: Healthcare

Employees: 7

Address: 3 Columbus Circle, New York, NY 10019

Phone: 347 480 9760

Last updated: 2024-12-31

Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc. logo
Market Cap: Highest
Employees: Medium

CAPLYTA

Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on developing novel drugs for the treatment of neuropsychiatric and neurologic diseases targeting intracellular signaling in the central nervous system. Key products include CAPLYTA for schizophrenia and ongoing developments in treatments for bipolar depression, autism spectrum disorder, and more.

Tags: biopharmaceutical, bipolar depression, central nervous system, drug development, neurologic diseases, neuropsychiatric, schizophrenia

Symbol: ITCI

Recent Price: $83.48

Industry: Drug Manufacturers - Specialty & Generic

CEO: Dr. Sharon Mates Ph.D.

Sector: Healthcare

Employees: 610

Address: 430 East 29th Street, New York, NY 10016

Phone: 646 440 9333

Leadership

  • Sharon Mates, Ph.D., Chairman, Founder & Chief Executive Officer
  • Michael I. Halstead, J.D., President
  • Mark Neumann, Executive Vice President, Chief Commercial Officer
  • Suresh Durgam, M.D., Executive Vice President, Chief Medical Officer
  • Sanjeev Narula, Executive Vice President, Chief Financial Officer
  • John A. Bardi, Senior Vice President, Market Access, Policy and Government Affairs
  • Robert E. Davis, Ph.D., Senior Vice President, Chief Scientific Officer
  • Karen Sheehy, Esq., Senior Vice President and Chief Compliance Officer
  • Michael Olchaskey, Pharm.D., Senior Vice President, Head of Regulatory Affairs
  • Juan Sanchez, M.D., Vice President of Corporate Communications and Investor Relations
  • Willie R. Earley, M.D., Senior Vice President, Head of Clinical Development
  • Joel S. Marcus, J.D., CPA, Executive Chairman & Founder
  • Rory B. Riggs, MBA, Co-Founder and Director
  • E. Rene Salas, CPA, Former Senior Client Partner at Ernst & Young, LLP; Former CFO, Wellstat, LLC
  • Robert L. Van Nostrand, Chairman, Metabolix; Board Member, Achillion Pharmaceuticals; Former CFO, OSI Pharmaceuticals

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

Quince Therapeutics, Inc.

Quince Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

NOV004

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases, with a bone-targeting drug platform and lead compound NOV004 designed to target bone fracture and disease sites.

Tags: NOV004, biopharmaceutical, biotechnology, bone-targeting, precision therapeutics, rare diseases

Symbol: QNCX

Recent Price: $1.85

Industry: Biotechnology

CEO: Dr. Dirk Thye M.D.

Sector: Healthcare

Employees: 32

Address: 601 Gateway Blvd, South San Francisco, CA 94080

Phone: 415 910 5717

Last updated: 2024-12-31

TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

TTX-MC138

Trans Code Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing drugs and diagnostics for treating metastatic disease. Their lead product, TTX-MC138, is aimed at metastatic cancer treatment, along with a range of other therapeutic platforms targeting cancer through innovative RNA- and CRISPR-based technologies.

Tags: CRISPR technology, RNA-based therapy, biopharmaceutical, cancer treatment, metastatic disease

Symbol: RNAZ

Recent Price: $3.76

Industry: Biotechnology

CEO: Mr. Thomas A. Fitzgerald M.B.A.

Sector: Healthcare

Employees: 10

Address: 6 Liberty Square, Boston, MA 02109

Phone: 857-837-3099

Last updated: 2024-12-31

Tempest Therapeutics, Inc.

Tempest Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

TPST-1495, TPST-1120, TREX-1

Tempest Therapeutics Inc. is a clinical-stage oncology company developing small molecule therapeutics to treat cancer, with key programs in TPST-1495 and TPST-1120, and research in TREX-1 enzyme modulation.

Tags: biotechnology, cancer treatment, clinical-stage, drug development, immune response, oncology, small molecule therapeutics

Symbol: TPST

Recent Price: $0.84

Industry: Biotechnology

CEO: Mr. Stephen R. Brady J.D., LLM

Sector: Healthcare

Employees: 17

Address: 7000 Shoreline Court, South San Francisco, CA 94080

Phone: 415 798 8589

Last updated: 2024-12-31

Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

XTX101

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients with a focus on tumor-selective therapies.

Tags: biotechnology, cancer treatment, checkpoint inhibitors, clinical-stage, immunotherapies

Symbol: XLO

Recent Price: $0.97

Industry: Biotechnology

CEO: Dr. Rene Russo BCPS, Pharm.D.

Sector: Healthcare

Employees: 73

Address: 828 Winter Street, Waltham, MA 02451

Phone: 617 430 4680

Last updated: 2024-12-31

Xencor, Inc.

Xencor, Inc. logo
Market Cap: High
Employees: Low

Monoclonal Antibody and Cytokine Therapeutics

Xencor, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of engineered monoclonal antibody and cytokine therapeutics for treating cancer and autoimmune diseases.

Tags: autoimmune diseases, biopharmaceutical, cancer treatment, cytokines, monoclonal antibodies

Symbol: XNCR

Recent Price: $23.71

Industry: Biotechnology

CEO: Dr. Bassil I. Dahiyat Ph.D.

Sector: Healthcare

Employees: 280

Address: 111 West Lemon Avenue, Monrovia, CA 91016

Phone: 626 305 5900

Last updated: 2024-12-31

Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. logo
Market Cap: Low
Employees: Lowest

NXP800, NXP900

Nuvectis Pharma, Inc., is a biopharmaceutical company that focuses on developing precision medicines for treating serious unmet medical needs in oncology. It is working on products like NXP800, a heat shock factor 1 pathway inhibitor, and NXP900, a drug candidate targeting Proto-oncogene c-Src and YES1 kinases.

Tags: NXP800, NXP900, biopharmaceutical, oncology, precision medicine

Symbol: NVCT

Recent Price: $5.14

Industry: Biotechnology

CEO: Mr. Ron Bentsur M.B.A.

Sector: Healthcare

Employees: 13

Address: 1 Bridge Plaza, Fort Lee, NJ 07024

Phone: 201 614 3150

Last updated: 2024-12-31